
In collaboration with
Samarkand State Medical University
Gold Open Access
All articles published in Clinical & Molecular Biomedicine (CMB) are made available through a fully open-access model, ensuring immediate and unrestricted access to readers worldwide.
Clinical & Molecular Biomedicine follows a single anonymized peer review process. Submissions are initially assessed by the editors to determine suitability for publication. If a submission is considered suitable, it is typically sent to a minimum of two reviewers for independent expert assessment of scientific quality.
No article processing charges are currently required for publication.
Possible editorial decisions include:
• Accept
• Minor revision
• Major revision
• Reject
The Editor-in-Chief has final authority over all editorial decisions.
Clinical & Molecular Biomedicine accepts the following manuscript categories:
• Original Research Articles
• Review Articles
• Short Communications
• Case Reports
• Methods and Protocols
• Letters to the Editor
The journal focuses on translational biomedical research integrating molecular biology, clinical medicine, and emerging biomedical technologies, including:
• Translational medicine
• Molecular and cellular biology
• Clinical biochemistry
• Genomics and epigenetics
• Proteomics and metabolomics
• Microbiome research
• Molecular oncology
• Neurobiology
• Biomarker discovery
• Drug discovery and resistance
• Gene and cell therapy
• Precision medicine
• Immunology and vaccinology
Clinical & Molecular Biomedicine follows internationally recognized publication ethics guidelines from the following organizations:
• Committee on Publication Ethics (COPE)
• International Committee of Medical Journal Editors (ICMJE)
• World Association of Medical Editors (WAME)
Ethical requirements include original research, no plagiarism or duplicate publication, accurate reporting of data, proper citation of sources, and ethical approval for human and animal research.
Authors retain full copyright ownership of their work. By choosing open access publication, authors agree to publish their article under a Creative Commons Attribution (CC BY) license, which permits redistribution, reuse and adaptation, and commercial use, provided that appropriate credit is given to the original authors and source.
Key aspects of the open access policy include:
• Immediate and unrestricted access to all articles
• Publication under the CC BY license, enabling broad reuse with proper attribution
• Promotion of equitable access to scientific knowledge regardless of institutional or financial constraints